{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:34:58Z","timestamp":1784237698361,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12094-018-02026-2","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T02:53:04Z","timestamp":1547002384000},"page":"1076-1084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost\u2013utility analysis of germline BRCA1\/2 testing in women with high-grade epithelial ovarian cancer in Spain"],"prefix":"10.1007","volume":"21","author":[{"given":"Carlota","family":"Moya-Alarc\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-0961","authenticated-orcid":false,"given":"Almudena","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"P\u00e9rez-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Bayo-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"S\u00e1nchez-Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"2026_CR1","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12094-016-1607-9","volume":"19","author":"J Galceran","year":"2017","unstructured":"Galceran J, Ameijide A, Carulla M, Mateos A, Quir\u00f3s JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19:799\u2013825.","journal-title":"Clin Transl Oncol"},{"key":"2026_CR2","unstructured":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica (SEOM). Las cifras del c\u00e1ncer en Espa\u00f1a 2018. 2018."},{"key":"2026_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ygyno.2016.11.019","volume":"144","author":"M Matz","year":"2017","unstructured":"Matz M, Coleman MP, Carreira H, Salmer\u00f3n D, Chirlaque MD, Allemani C. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 2017;144:396\u2013404.","journal-title":"Gynecol Oncol"},{"key":"2026_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","volume":"22","author":"A Liede","year":"2004","unstructured":"Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22:735\u201342.","journal-title":"J Clin Oncol"},{"key":"2026_CR5","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313:1347.","journal-title":"JAMA"},{"key":"2026_CR6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. JNCI J Natl Cancer Inst. 2013;105:812\u201322.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s12094-011-0701-2","volume":"13","author":"B Gra\u00f1a","year":"2011","unstructured":"Gra\u00f1a B, Lastra E, Llort G, Brunet J, Isla D. SEOM clinical guidelines for hereditary cancer. Clin Transl Oncol. 2011;13:580.","journal-title":"Clin Transl Oncol"},{"key":"2026_CR8","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30:2654\u201363.","journal-title":"J Clin Oncol"},{"key":"2026_CR9","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12094-015-1435-3","volume":"17","author":"G Llort","year":"2015","unstructured":"Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, Teul\u00e9 A, et al. SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin Transl Oncol. 2015;17:956.","journal-title":"Clin Transl Oncol"},{"key":"2026_CR10","doi-asserted-by":"publisher","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","volume":"27","author":"S Paluch-Shimon","year":"2016","unstructured":"Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016;27:v103\u201310.","journal-title":"Ann Oncol"},{"key":"2026_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jval.2017.01.004","volume":"20","author":"A Eccleston","year":"2017","unstructured":"Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, et al. A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer. Value Health. 2017;20:567\u201376.","journal-title":"Value Health"},{"key":"2026_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10689-017-9985-x","volume":"16","author":"X Gabald\u00f3 Barrios","year":"2017","unstructured":"Gabald\u00f3 Barrios X, Sarabia Meseguer MD, Mar\u00edn Vera M, S\u00e1nchez Berm\u00fadez AI, Mac\u00edas Cerrolaza JA, S\u00e1nchez Henarejos P, et al. Molecular characterization and clinical interpretation of BRCA1\/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical\u2013pathological features in BRCA carriers and non-carriers. Fam Cancer. 2017;16:477\u201389.","journal-title":"Fam Cancer"},{"key":"2026_CR13","unstructured":"Evoluci\u00f3n del test gen\u00e9tico de BRCA1 y BRCA2 en pacientes con c\u00e1ncer de mama u ovario a lo largo de una d\u00e9cada. SEOM 2015. 2015. \n                    http:\/\/www.postersessiononline.es\/312191188_es\/congresos\/15seom\/aula\/-P_192_15seom.pdf\n                    \n                  . Accessed 25 Oct 2017."},{"key":"2026_CR14","doi-asserted-by":"publisher","first-page":"iii21","DOI":"10.1093\/annonc\/mdq082","volume":"21","author":"MD Chirlaque","year":"2010","unstructured":"Chirlaque MD, Salmer\u00f3n D, Ardanaz E, Galceran J, Mart\u00ednez R, Marcos-Gragera R, et al. Cancer survival in Spain: estimate for nine major cancers. Ann Oncol. 2010;21:iii21\u20139.","journal-title":"Ann Oncol"},{"key":"2026_CR15","unstructured":"Instituto Nacional de Estadistica. (Spanish Statistical Office). \n                    http:\/\/www.ine.es\/en\/welcome.shtml\n                    \n                  . Accessed 7 Jun 2018."},{"key":"2026_CR16","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews\u00ae. Seattle: University of Washington; 2016. \n                    http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/\n                    \n                  . Accessed 22 Mar 2018."},{"key":"2026_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1200\/JCO.2010.31.6752","volume":"29","author":"A Alonso-Babarro","year":"2011","unstructured":"Alonso-Babarro A, Bruera E, Varela-Cerdeira M, Boya-Cristia MJ, Madero R, Torres-Vigil I, et al. Can this patient be discharged home? Factors associated with at-home death among patients with cancer. J Clin Oncol. 2011;29:1159\u201367.","journal-title":"J Clin Oncol"},{"key":"2026_CR18","doi-asserted-by":"publisher","first-page":"e012576","DOI":"10.1136\/bmjopen-2016-012576","volume":"6","author":"MI Bennett","year":"2016","unstructured":"Bennett MI, Ziegler L, Allsop M, Daniel S, Hurlow A. What determines duration of palliative care before death for patients with advanced disease? A retrospective cohort study of community and hospital palliative care provision in a large UK city. BMJ Open. 2016;6:e012576.","journal-title":"BMJ Open"},{"key":"2026_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/0269216312442973","volume":"27","author":"A Alonso-Babarro","year":"2013","unstructured":"Alonso-Babarro A, Astray-Mochales J, Dominguez-Berjon F, Genova-Maleras R, Bruera E, Diaz-Mayordomo A, et al. The association between in-patient death, utilization of hospital resources and availability of palliative home care for cancer patients. Palliat Med. 2013;27:68\u201375.","journal-title":"Palliat Med"},{"key":"2026_CR20","unstructured":"Ministerio de Sanidad, Servicios Sociales e Igualdad. Instituto de Informaci\u00f3n Sanitaria. Registro de altas. 2015."},{"key":"2026_CR21","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jpainsymman.2010.02.026","volume":"40","author":"X G\u00f3mez-Batiste","year":"2010","unstructured":"G\u00f3mez-Batiste X, Porta-Sales J, Espinosa-Rojas J, Pascual-L\u00f3pez A, Tuca A, Rodriguez J. Effectiveness of palliative care services in symptom control of patients with advanced terminal cancer: a Spanish, multicenter, prospective, quasi-experimental, pre-post study. J Pain Symptom Manag. 2010;40:652\u201360.","journal-title":"J Pain Symptom Manag"},{"key":"2026_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/0269216309359996","volume":"24","author":"A Alonso-Babarro","year":"2010","unstructured":"Alonso-Babarro A, Varela-Cerdeira M, Torres-Vigil I, Rodr\u00edguez-Barrientos R, Bruera E. At-home palliative sedation for end-of-life cancer patients. Palliat Med. 2010;24:486\u201392.","journal-title":"Palliat Med"},{"key":"2026_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1017\/S1478951514000200","volume":"13","author":"C Calvo-Espinos","year":"2014","unstructured":"Calvo-Espinos C, Ruiz de Gaona E, Gonzalez C, Ruiz de Galarreta L, Lopez C. Palliative sedation for cancer patients included in a home care program: a retrospective study. Palliat Support Care. 2014;13:619\u201324.","journal-title":"Palliat Support Care"},{"key":"2026_CR24","unstructured":"Mediana de los costes de los Boletines Oficiales de las Comunidades Aut\u00f3nomas. 2017."},{"key":"2026_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","volume":"24","author":"JL Bastida","year":"2010","unstructured":"Bastida JL, Oliva J, Anto\u00f1anzas F, Garc\u00eda-Alt\u00e9s A, Gisbert R, Mar J, et al. Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias. Gac Sanit. 2010;24:154\u201370.","journal-title":"Gac Sanit"},{"key":"2026_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-0986-y","author":"L Delgado-Ortega","year":"2018","unstructured":"Delgado-Ortega L, Gonz\u00e1lez-Dom\u00ednguez A, Borras J, Oliva J, Gonz\u00e1lez-Haba E, Menj\u00f3n S, et al. The economic burden of disease of epithelial ovarian cancer in Spain. The Ovarcost Study. Eur J Health Econ. 2018. \n                    https:\/\/doi.org\/10.1007\/s10198-018-0986-y\n                    \n                  .","journal-title":"Eur J Health Econ"},{"key":"2026_CR27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12885-017-3926-9","volume":"18","author":"S Garc\u00eda-Gutierrez","year":"2018","unstructured":"Garc\u00eda-Gutierrez S, Sarasqueta C, Legarreta MJ, Gonzalez N, Redondo M, Rivero A, et al. Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study. BMC Cancer. 2018;18:54.","journal-title":"BMC Cancer"},{"key":"2026_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4321\/S1135-57272015000100010","volume":"89","author":"A Arrospide","year":"2015","unstructured":"Arrospide A, Soto-Gordoa M, Acaiturri T, L\u00f3pez-Vivanco G, Abecia LC, Mar J. Cost of breast cancer treatment by clinical stage in the Basque Country, Spain. Rev Esp Salud P\u00fablica. 2015;89:93\u20137.","journal-title":"Rev Esp Salud P\u00fablica"},{"key":"2026_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S1470-2045(13)70442-X","volume":"14","author":"R Luengo-Fernandez","year":"2013","unstructured":"Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165\u201374.","journal-title":"Lancet Oncol"},{"key":"2026_CR30","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Ficha T\u00e9cnica Arimidex 1\u00a0mg comprimidos recubiertos con pel\u00edcula. 2014. In: AEMPS. \n                    https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/61286\/FT_61286.html\n                    \n                  . Accessed 19 Feb 2018."},{"key":"2026_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","volume":"113","author":"LJ Havrilesky","year":"2009","unstructured":"Havrilesky LJ, Broadwater G, Davis DM, Nolte KC, Barnett JC, Myers ER, et al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol. 2009;113:216\u201320.","journal-title":"Gynecol Oncol"},{"key":"2026_CR32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/erp.10.65","volume":"10","author":"T Peasgood","year":"2010","unstructured":"Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2010;10:553\u201366.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026_CR33","unstructured":"National Institute for Clinical Excellence (NICE). Cost-effectiveness evidence review. Familial breast cancer: classification and care of women at risk of familial breast cancer and management of breast cancer and related risk in people with a family history of breast cancer. 2013."},{"key":"2026_CR34","unstructured":"Kind P, Hardman G, Macran S. UK population norms for EQ-5D. In: Centre for Health Economics, University of York; 1999. \n                    https:\/\/econpapers.repec.org\/paper\/chyrespap\/172chedp.htm\n                    \n                  . Accessed 29 Aug 2018."},{"key":"2026_CR35","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10549-010-1043-4","volume":"125","author":"VR Grann","year":"2011","unstructured":"Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, et al. Comparative effectiveness of screening and prevention strategies among BRCA1\/2-affected mutation carriers. Breast Cancer Res Treat. 2011;125:837\u201347.","journal-title":"Breast Cancer Res Treat"},{"key":"2026_CR36","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.2010.33.1561","volume":"29","author":"CH Halbert","year":"2011","unstructured":"Halbert CH, Stopfer JE, McDonald J, Weathers B, Collier A, Troxel AB, et al. Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: Does time heal women\u2019s concerns? J Clin Oncol. 2011;29:4302\u20136.","journal-title":"J Clin Oncol"},{"key":"2026_CR37","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s10897-015-9899-4","volume":"25","author":"AS Sie","year":"2016","unstructured":"Sie AS, Spruijt L, van Zelst-Stams WAG, Mensenkamp AR, Ligtenberg MJL, Brunner HG, et al. High satisfaction and low distress in breast cancer patients one year after BRCA-mutation testing without prior face-to-face genetic counseling. J Genet Couns. 2016;25:504\u201314.","journal-title":"J Genet Couns"},{"key":"2026_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jamadermatol.2016.4518","volume":"153","author":"L Pil","year":"2017","unstructured":"Pil L, Hoorens I, Vossaert K, Kruse V, Tromme I, Speybroeck N, et al. Cost-effectiveness and budget effect analysis of a population-based skin cancer screening. JAMA Dermatol. 2017;153:147\u201353.","journal-title":"JAMA Dermatol"},{"key":"2026_CR39","first-page":"45","volume":"39","author":"E D\u2019Andrea","year":"2015","unstructured":"D\u2019Andrea E, Marzuillo C, Pelone F, Vito CD, Villari P. Genetic testing and economic evaluations: a systematic review of the literature. Epidemiol Prev. 2015;39:45\u201350.","journal-title":"Epidemiol Prev"},{"key":"2026_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/2050640617722902","volume":"6","author":"M Areia","year":"2018","unstructured":"Areia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: a cost-utility analysis for countries with an intermediate gastric cancer risk. United Eur Gastroenterol J. 2018;6:192\u2013202.","journal-title":"United Eur Gastroenterol J."},{"key":"2026_CR41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10198-016-0851-9","volume":"18","author":"A Neumann","year":"2017","unstructured":"Neumann A, Lindholm L, Norberg M, Schoffer O, Klug SJ, Norstr\u00f6m F. The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program. Eur J Health Econ. 2017;18:905\u201319.","journal-title":"Eur J Health Econ"},{"key":"2026_CR42","doi-asserted-by":"publisher","first-page":"e0145548","DOI":"10.1371\/journal.pone.0145548","volume":"11","author":"SK Naber","year":"2016","unstructured":"Naber SK, Matthijsse SM, Rozemeijer K, Penning C, de Kok IMCM, van Ballegooijen M. Cervical cancer screening in partly HPV vaccinated cohorts\u2014a cost-effectiveness analysis. PLoS ONE. 2016;11:e0145548.","journal-title":"PLoS ONE"},{"key":"2026_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-017-0887-5","author":"D M\u00fcller","year":"2017","unstructured":"M\u00fcller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, et al. Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. Eur J Health Econ. 2017. \n                    https:\/\/doi.org\/10.1007\/s10198-017-0887-5\n                    \n                  .","journal-title":"Eur J Health Econ"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-02026-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-018-02026-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-02026-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T18:15:52Z","timestamp":1589998552000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-018-02026-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s12094-018-02026-2","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"13 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors Carlota Moya-Alarc\u00f3n and Susana Simon are employees of AstraZeneca Farmaceutica Spain. Authors Almudena Gonzalez-Dom\u00ednguez and Ines Perez-Roman work in Weber, enterprise that received fees from AstraZenena Farmaceutica Spain. Authors Antonio Gonzalez-Mart\u00edn, Elo\u00edsa Bayo-Lozano and Ana Beatriz S\u00e1nchez-Heras have participated as experts for Weber, enterprise that received consulting fees from AstraZeneca Farmaceutica Spain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed Consent is not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}